Category: movement disorders

Biogen to seek approval for high-dose version of Spinraza for SMA

Over the past decade, three drugs—Biogen’s Spinraza, Roche’s Evrysdi, and Novartis’ gene therapy Zolgensma—have transformed spinal muscular atrophy (SMA) treatment. However, unmet needs remain. Biogen, the first to receive SMA approval in 2016, is addressing this with a higher dose of Spinraza (nusinersen). In Biogen’s phase 2/3 DEVOTE study, the higher dose significantly improved motor…